Concepedia

Magdy Elkhashab

ME

Statistics

Publications

31

Citations

2.8K

H-Index

23

Active since

2013

Affiliations

Toronto Liver Centre(Current)

Gilead Sciences (United States)

University of Toronto

Texas Liver Institute

Chinese University of Hong Kong

Magdy Elkhashab is an author at Toronto Liver Centre specializing in pharmacotherapy, viral hepatitis, and viral hepatitis treatment.

Publications per year

2013–2023

31

Publications

31

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

, , +12

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Keyur Patel, Stephen A. Harrison, Magdy Elkhashab et al. · Hepatology · 2020 · 321 citations

, , +17

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 278 citations

, , +17

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis et al. · Clinical Gastroenterology and Hepatology · 2017 · 230 citations · Full text

, , +17

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Saumya Jayakumar, Michael S. Middleton, Eric Lawitz et al. · Journal of Hepatology · 2018 · 206 citations

, , +17

1–5 of 31